Fig. 8. Expression of INPP5B alters trafficking of ERGIC53 in BFA-treated cells. (A) HeLa cells transiently expressing GFP-INPP5B (green) were incubated with 5 µg/ml BFA at 37°C for 20 minutes before fixation in paraformaldehyde and labelling with antibodies against ERGIC53, GM130 or GalNacT2 (red). (B) HeLa cells expressing GFP-INPP5B (green) were incubated with 5 µg/ml BFA for the indicated times and labelled with an antibody against ERGIC53 (red). (C) HeLa cells expressing GFP-INPP5B were incubated with or without 5 µg/ml BFA for 5 minutes and labelled with antibody against β-COP (red). (D) HeLa cells transiently expressing GFP-INPP5B or GFP-OCRL1 (green) were incubated with 5 µg/ml BFA for 20 minutes and labelled with antibody against ERGIC53. Bars, 10 µm.